106 related articles for article (PubMed ID: 17933545)
1. A performance evaluation of 90Y dose-calibrator measurements in nuclear pharmacies and clinics in the United States.
Schultz MK; Cessna JT; Anderson TL; Ponto JA; Petry N; Kowalsky RJ; Palmer MR; Beinlich UF; Baker W; Hinkle GH; Hung JC; Quinton T; Rice PA; Divgi C; Norenberg JP
Appl Radiat Isot; 2008 Feb; 66(2):252-60. PubMed ID: 17933545
[TBL] [Abstract][Full Text] [Related]
2. Experimental determination of calibration settings for plastic syringes containing solutions of 90Y using commercial radionuclide calibrators.
Zimmerman BE; Cessna JT; Millican MA
Appl Radiat Isot; 2004; 60(2-4):511-7. PubMed ID: 14987694
[TBL] [Abstract][Full Text] [Related]
3. Development of activity standard for 90 Y microspheres.
Mo L; Avci B; James D; Simpson B; Van Wyngaardt WM; Cessna JT; Baldock C;
Appl Radiat Isot; 2005 Aug; 63(2):193-9. PubMed ID: 15963429
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of different beta-counting systems involved in 90Y-Zevalin quality control.
Urbano N; Modoni S
Nucl Med Commun; 2007 Dec; 28(12):943-50. PubMed ID: 18090222
[TBL] [Abstract][Full Text] [Related]
5. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
Marcus R
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
[TBL] [Abstract][Full Text] [Related]
6. Resin 90Y microsphere activity measurements for liver brachytherapy.
Dezarn WA; Kennedy AS
Med Phys; 2007 Jun; 34(6):1896-900. PubMed ID: 17654890
[TBL] [Abstract][Full Text] [Related]
7. Radioassay of yttrium-90 radiation using the radionuclide dose calibrator.
Salako QA; DeNardo SJ
J Nucl Med; 1997 May; 38(5):723-6. PubMed ID: 9170436
[TBL] [Abstract][Full Text] [Related]
8. Accurate dose calibrator activity measurement of 90Y-ibritumomab tiuxetan.
Siegel JA; Zimmerman BE; Kodimer K; Dell MA; Simon WE
J Nucl Med; 2004 Mar; 45(3):450-4. PubMed ID: 15001686
[TBL] [Abstract][Full Text] [Related]
9. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin).
Tennvall J; Fischer M; Bischof Delaloye A; Bombardieri E; Bodei L; Giammarile F; Lassmann M; Oyen W; Brans B; ; ;
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):616-22. PubMed ID: 17323056
[TBL] [Abstract][Full Text] [Related]
10. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
[TBL] [Abstract][Full Text] [Related]
11. Transfer standard for beta decay radionuclides in radiotherapy.
Thieme K; Beinlich U; Fritz E
Appl Radiat Isot; 2004; 60(2-4):519-22. PubMed ID: 14987695
[TBL] [Abstract][Full Text] [Related]
12. Development of anthropomorphic hand phantoms for personal dosimetry in 90Y-Zevalin preparation and patient delivering.
Ciolini R; d'Errico F; Traino AC; Paternostro E; Laganà A; Romei C; Pazzagli F; Del Gratta A
Radiat Prot Dosimetry; 2014 Jan; 158(2):216-20. PubMed ID: 23960242
[TBL] [Abstract][Full Text] [Related]
13. The traceability chain of 131I measurements for nuclear medicine in Cuba.
Oropesa P; Moreno Y; Serra RA; Hernández AT
Appl Radiat Isot; 2012 Sep; 70(9):2251-4. PubMed ID: 22534014
[TBL] [Abstract][Full Text] [Related]
14. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma.
Grillo-López AJ
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S44-9. PubMed ID: 15786025
[TBL] [Abstract][Full Text] [Related]
15. 90Sr content in 90Y-labeled SIR-spheres and Zevalin.
Metyko J; Erwin W; Poston J; Jimenez S
Health Phys; 2014 Nov; 107(5 Suppl 3):S177-80. PubMed ID: 25272027
[TBL] [Abstract][Full Text] [Related]
16. A comparison of techniques for analysing 90Y-Zevalin thin-layer chromatography plates.
O'Brien LM; Waight CC; Millar AM
Nucl Med Commun; 2005 Feb; 26(2):163-6. PubMed ID: 15657511
[TBL] [Abstract][Full Text] [Related]
17. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS
J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494
[TBL] [Abstract][Full Text] [Related]
18. Comparison of (90)Y activity measurements in nuclear medicine in Germany.
Kossert K; Bokeloh K; Ehlers M; Nähle O; Scheibe O; Schwarz U; Thieme K
Appl Radiat Isot; 2016 Mar; 109():247-249. PubMed ID: 26597654
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic imaging prior to 90Y-ibritumomab tiuxetan (Zevalin) treatment in follicular non-Hodgkin's lymphoma.
Otte A
Hell J Nucl Med; 2008; 11(1):12-5. PubMed ID: 18392220
[TBL] [Abstract][Full Text] [Related]
20. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
